Current Illinois CancerCare Clinical Trials

Daratumumab/rHuPh20 +/- Lenalidomide as Post-ASCT Maintenance for MM w/MRD to Direct Therapy Duration (DRAMMATIC)

Study Number: S1803

Status: Open

Study Coordinator(s)
  • Navigator Heather, 309-243-3661 hthulean@illinoiscancercare.com
  • Hannah, 309-243-3628 hknight@illinoiscancercare.com

Study Link

« Search Again